

SH/EAHP WORKSHOP 2017

CASE 210 PRESENTATION

Jonathon H Gralewski DO, MS, Ginell R Post MD, PhD,
Youzhong Yuan MD

September 9, 2017

UAMS



COLLEGE OF MEDICINE
DEPARTMENT OF PATHOLOGY



UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES

Clinical History

- 60 year old male with history of c-MAF high-risk IgG lambda plasma cell myeloma (December 2015)
- Chemotherapeutic intervention included VD-PACE induction, PACMED cytoreduction and carfilzomib and melphalan-based autologous stem cell transplant
- Follow up in November 2016
 - Bone marrow was negative for plasma cell myeloma
 - Abnormal findings seen on PET-CT imaging
 - Extramedullary disease progression versus infection

Imaging Studies and Physical Exam

- PET-CT (November 2016)
 - Increased uptake in left posterior ilium, right proximal humerus and right perineum
- PET-CT (January 2017)
 - Increased uptake in right perineum
 - Mediastinal lymph nodes and lung
 - Left lobe of liver
- Physical exam revealed soft tissue swelling in the left gingiva




Nov 2016









Jan 2017

Mediastinal Lymph Node




Diff-Quik preparation ($\times 500$): Large atypical cells with immature chromatin

Flow Cytometric Analysis: Mediastinal lymph node



- CD45 vs side scatter identified a cell population in the monocyte region with high forward scatter comprising 40% of total events (red). This population was positive for CD33, HLA-DR, CD14 (bright), CD11b (bright), CD36 (variable) and negative for CD34 and CD117.
- A second population (21%; blue) with decreased forward and side scatter showed variable expression of CD33 and HLA-DR with dimmer CD11b and CD14.


Mediastinal Lymph Node




H&E stain ($\times 40$ and $\times 400$): Aggregates of large atypical cells with rare intermingled granulocytes

Mediastinal Lymph Node: IHC


CD163




CD138




Lysozyme



MPO




Left Gingival Biopsy



H&E stain (×20): Dense dermal infiltrate

Left Gingival Biopsy




H&E stain ($\times 200$ left; $\times 400$ right): Atypical cellular infiltrate within the dermis


Left Gingival Biopsy

Immunohistochemical Stains


MPO




LYSOZYME



CD163




CD138



Ancillary Studies

- **FISH Analysis:**
 - **Mediastinal lymph node:**
 - Positive for t(14;16)(q32;q23) translocation (76%)
 - Negative for t(11q23) and del(17p13.1)
 - **Gingival biopsy:**
 - Positive for t(14;16)(q32;q23) translocation (73%)
 - Negative for t(9;22)(q34;q11.2) and inv (16)
- **Cytogenetic Analysis:**
 - **Unsuccessful due to no growth and low mitotic index**
- **Concurrent bone marrow and MRD flow cytometry were negative for PCM**

MEDIASTINAL LYMPH NODE






FISH with dual color probes showing IGH (14q32; green) and MAF (16q23; red) gene rearrangement (pattern 2R1G1F)

Case Summary

- **Morphology:**
 - Atypical infiltrates resembling monocyte-macrophage cells
 - Multiple locations (left gingiva, mediastinal lymph node, right perineum and liver)
- **Immunophenotype:**
 - Positive for CD68, CD163, lysozyme, CD43, MPO (subset)
 - Negative for CD34, CD117, S-100, Pan-CK, CD138 and CD56
- **Molecular Analysis:**
 - t(14;16)(q32;q23) translocation; IgH and MAF genes

IgH rearrangement (Mediastinal LN)



Genomic Studies (NGS)

Bone marrow 2015

Gingival Lesion 2017

IGH *IGH*-MAF rearrangement

IGH *IGH*-MAF rearrangement

CDKN2A/B loss

CDKN2A/B loss

KRAS A146V

KRAS A146V

BRAF1 G469A, *BRAF1* G466A

BRAF1 G469A

MAP3K6 Q943, truncation exon 22

MAP3K6 Q943, truncation intron 22

TRAF3 R505

TNFAIP3 W85

PTPRO E379K

NF1 R2450

CCT6B splice site 615 2A>G

c-MAF Role in PCM Oncogenesis

- Located on chromosome 16q23.2
- Member of the AP-1 superfamily
 - Oncogene that is a bZIP transcription factor (Tf)
 - Other AP-1 Tfs include *Fos* and *Jun*
- Oncogenesis in PCM
 - *MAF* translocations are seen in ~5% of PCM, but ~50% of PCM demonstrate *MAF* overexpression
 - Regulated via post-translational modification (GSK3 and sumoylation)

Plasma Cell Myeloma

Recurrent primary
IgH translocation
t(14;16)

~ 5-10%

c-maf
oncogene

overexpression
in ~ 50% of myelomas

Overexpression by
unknown mechanisms

~ 40%

Molecular targets of *c-maf* transactivation

Cyclin D2


ARK5

Integrin β7




Cell cycle
progression

Proliferation



Akt activation
Migration and Invasion

Tumor survival
and expansion



1. Increased adhesion
2. Increased VEGF secretion

Tumor-stroma
interactions

Cell Transformation/Evolution

- Hematopoietic cells are derived from common precursors that as they differentiate, they become committed to a specific lineage
- However, cases have shown that two hematopoietic tumor populations can share identical genetic abnormalities but be phenotypically distinct¹
 - Clonal relationship
 - Lineage plasticity


1. Feldman, A. L., Arber, D. A., Pittaluga, S., Martinez, A., Burke, J. S., Raffeld, M., Camos, M., Warnke, R., & Jaffe, E. S. Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone. *Blood*, (2008).

Transdifferentiation

- Three mechanisms/pathways^{2,3}:
 1. Direct transdifferentiation
 - a) Neoplastic cells differentiate into distinct phenotypic cells via epigenetics and genetics
 2. Two step de-differentiation
 - a) Neoplastic cells de-differentiate into a earlier progenitor cell then regain the capability to re-differentiate along a different lineage
 3. Common progenitor cell
 - a) Pluripotent neoplastic cell evolves into separate cell lineages at different times
 - b) Retains a genotype or genotypic signature linked to the progenitor cell

2. Ansari J *et al.* Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis and treatment. *European J of Haematology* (2016).

3. Stoecker M, Wang E. Histiocytic/Dendritic cell transformation of B-Cell Neoplasms. *Arch Pathol Lab Med* (2013).



Proposed Diagnosis

**Myeloid sarcoma with monocytic differentiation
and IGH-MAF gene rearrangement**

Final Panel Diagnosis

**Histiocytic sarcoma (with *IGH-MAF*), likely
transdifferentiated from plasma cell myeloma
(with *IGH-MAF*)**